Form 4: Inmune Bio Director Timothy Schroeder Acquires Options Under 2021 Stock Incentive Plan

Director Timothy Schroeder acquired 12,500 options in Inmune Bio, Inc. under the company's 2021 Stock Incentive Plan.

Summary

• On May 14, 2024, Timothy Schroeder, a director of Inmune Bio, Inc., acquired 12,500 options to purchase common stock.
• The options were granted pursuant to the 2021 Stock Incentive Plan.
• The exercise price of the options is $9.92.
• The options vest monthly over one year, becoming fully vested on May 14, 2025.
• The expiration date for the options is May 13, 2034.
• Following the transaction, Schroeder directly owns 12,500 derivative securities.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine grant of options, which is neither particularly positive nor negative on its own.

Positives

• The grant of options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages continued service and contribution to the company.

Industry Context

Stock options are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholder value.

Stakeholder Impact

• The option grant could potentially dilute existing shareholders if the options are exercised.

Key Dates